Clinical Trial Update: Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating sirolimus in end-stage renal disease among high-risk kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Graft-versus-host Disease
• Kidney Transplantation

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Chronic Kidney Failure, Graft vs Host Disease | Phase 4 | Status: COMPLETED